What is Excessive Daytime Sleepiness and market overview?

 

Excessive Daytime Sleepiness Market

In the case of sleep apnea, a continuous positive airway pressure (CPAP) machine can be used. Medication can also be prescribed for patients with narcolepsy to help them remain awake and productive during the day. Shift workers who persistently feel sleepy during work hours may also benefit from medication if adjusting sleep habits does not help, or if rotating schedules make it challenging to sleep sufficiently. In case of failure behavioral changes to improve sleep, medication may be an option.

Previously approved therapeutics includes Modafinil (Provigil) and armodafinil (Nuvigil), which are the possible medications to treat excessive sleepiness market. These medications work by changing the action of certain chemicals in the brain and have “monoaminergic” effects (altering neurotransmitters like dopamine and serotonin). Other possible medications are stimulants, such as methylphenidate (Ritalin).

Xyrem is a central nervous system (CNS) depressant that was FDA-approved in 2002. It is indicated for the treatment of cataplexy and daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy. In November 2018, the US Food and Drug Administration (FDA) approved Jazz Pharmaceuticals’ Xyrem for the treatment of pediatric patients aged 7–17 years with narcolepsy.

In March 2019, the Food and Drug Administration approved solriamfetol (Sunosi), a Jazzpharma product for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It was designated a Schedule IV medicine by the US Drug Enforcement Agency on June 17, 2019. Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to treat those conditions. Sunosi—phenylalanine derivative with the systematic name (R)-2amino-3-phenyl propyl carbamate hydrochloride—contains solriamfetol, which is dopamine and norepinephrine reuptake inhibitor (DNRI). It has also received orphan drug designation for narcolepsy in the United States.

Know More- Excessive Daytime Sleepiness Market Report